Verici Dx
Company Profile
Verici Dx (AIM: VRCI) is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
Latest Company Summary
Investor Access
There is no Investor Access event planned at the moment - click on "Register your Interest" and we'll tell the Company that you'd like to attend one in the future and update you when an event is planned.
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | June |
| Interim Results* | September |
| AGM* | July |
* Months based on previous announcements of this kind
